The Union Budget 2026-27 (presented on February 1, 2026) provides the following key allocations for the requested departments/agencies, based on the official Expenditure Budget documents (allsbe.pdf from indiabudget.gov.in).
We have included comparisons with the 2025-26 figures where available from prior budget documents and reports (note: 2025-26 figures reflect Budget Estimates [BE] or Revised Estimates from that year, often around ₹28,509 crore for DST, ₹3,447 crore for DBT, and ₹6,658 crore for CSIR in 2025-26).
Department of Biotechnology (DBT)
₹3,446 crore (all Revenue; no separate Capital break-out shown in summary).
Comparison with 2025-26: Similar to the BE 2025-26 allocation of ≈₹3,447 crore (a stabilization/maintenance level with marginal or no significant change). This core departmental funding supports ongoing biotech research, grants, and schemes.
Additional highlight: The new Biopharma Shakti scheme (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation) has a separate outlay of ₹10,000 crore over 5 years (≈₹2,000 crore annualized, though not part of the core DBT demand). This focuses on biologics, biosimilars, manufacturing, and positioning India as a global biopharma hub.
Council of Scientific and Industrial Research (CSIR)
₹6,765.62 crore total (Revenue: ₹6,760.29 crore + Capital: ₹5.33 crore).
Comparison with 2025-26: Slight increase from BE 2025-26 of ≈₹6,658 crore (or around ₹6,600-6,657 crore in various references), reflecting modest growth/stabilization for CSIR labs, industrial R&D, and national research programs.
Department of Science and Technology (DST)
₹28,049.32 crore total (Revenue: ₹7,963.94 crore + Capital: ₹20,085.38 crore).
Comparison with 2025-26: Comparable to the elevated BE 2025-26 of ≈₹28,509 crore (which included major corpus elements like the Research, Development and Innovation Fund). The 2026-27 figure shows continuity in high-level support for schemes like ANRF, AI/Quantum Missions, geospatial programs, and broader S&T innovation.
Indian Council of Medical Research (ICMR) ICMR falls under the Department of Health Research (DHR) in the Ministry of Health and Family Welfare (not under Science & Technology demands).
Allocation: ICMR specifically enhanced to ₹4,000 crore in BE 2026-27 (up from ≈₹3,150.50 crore in RE 2025-26, a ~27% increase). Broader DHR: ₹4,821.21 crore (including ICMR), marking a ~24% rise over prior year.
Comparison with 2025-26: Significant jump from previous levels, emphasizing medical research, clinical trials, surveillance, and innovation in health (e.g., NCDs, infectious diseases). This aligns with overall health ministry allocation rising ~10% to ₹1,06,530.42 crore.
These allocations reflect a continued push toward innovation, biopharma growth, and health research, with flagship schemes like Biopharma Shakti adding momentum beyond core departmental budgets. For exact breakdowns (including sub-schemes or any post-presentation revisions), refer to the official India Budget site: https://www.indiabudget.gov.in/ (Expenditure Budget PDFs, especially allsbe.pdf and individual demands 89, 90, 91).
 – With 2025-26 Comparison){kind=link}
0 Comments